Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial
-
By
-
Justin R. Ortiz
-
Drishya Kurup
-
Adam C. Kaufman
-
Sabrine Ben Hamed
-
Allison M. LaRocco
-
Kirsten E. Lyke
-
Sarah M. Litts
-
Shrimati Datta
-
Yuanyuan Liang
-
Megan F. McGilvray
-
Jeannie A. Losignor
-
Jennifer J. Oshinsky
-
Kari V. Palmer
-
Ifayet PL Johnson-Mayo
-
Gabrielle Scher
-
Uthra Balakumar
-
Anisha Chandwani
-
Rekha R. Rapaka
-
Meagan E. Deming
-
Joel V. Chua
-
Christoph Wirblich
-
Wilbur H. Chen
-
Kathleen M. Neuzil
-
Marcela F. Pasetti
-
Matthias J. Schnell
-
June 9, 2026
-
0 min
3 Topic Commentaries
Intracranial Hemorrhages, Central Nervous System Infections, Machine Learning
-
Dr. Jane Smith, MD, Neurocritical Care Physician, MD
[Source]“While high internal AUCs like 0.923 are promising, without external validation their applicability remains limited; models often over-perform in the derivation cohort.”
-
Dr. Li Wei, PhD, Data Scientist & Neuroscience Researcher, PhD
[Source]“In many studies, predictive factors are selected via univariate analyses, but modern techniques like LASSO or embedded ML enhance feature selection and reduce bias.”
-
Dr. Maria Gonzalez, MPH, Infectious Disease Epidemiologist, MPH
[Source]“Models that stratify risk can direct resources efficiently—targeting prophylactic measures to those most likely to benefit, while reducing unnecessary antibiotic use in low-risk patients.”
